Performance
Trailing returns
| 1 day |
| -1.63% | |||
| 1 week | +2.60% |
| |||
| 4 week | +5.21% |
| |||
| 3 month | +15.17% |
| |||
| YTD | +26.40% |
| |||
| 1 year | +34.65% |
| |||
| 3 years* | +25.03% |
| |||
| 5 years* | +16.21% |
| |||
| *annualized | |||||
| Best 3 month return | +26.98% | |
| Worst 3 month return | -27.60% |
Morningstar statistics
Morningstar category: Health
| Return | Risk | Rating | |
| 3 years | Above Average | Above Average |
 
|
| 5 years | Above Average | Above Average |
|
| 10 years | High | Above Average |
|
| Overall | High | Above Average |
|
Morningstar style Learn more
| Large | |||
| Mid | |||
| Small | |||
| Value | Blend | Growth |
Key statistics
| Total assets | 1.68B | |
| Front load | 5.50% | |
| Deferred load | - | |
| Expense ratio | 1.23% | |
| Management fee | - | |
| Fund family | Prudential Investments |
Asset allocation
| Cash | 3.98% | |
| Stocks | 92.00% | |
| Bonds | 0.00% | |
| Other | 4.02% |
Purchase information
| Initial | $2,500 | |
| Additional | $100 | |
| IRA Initial | $1,000 | |
| AIP Initial | $50 | |
| AIP Additional | $50 |
35.78+0.25(0.70%)
May 17, 4:00PM EDT
Overall Morningstar RatingTM
Description
The investment seeks long-term capital appreciation. The fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector. It will invest in securities of issuers among a number of different countries throughout the world, one of which may be the United States. The portfolio managers use fundamental and quantitative analyses to select individual securities, and they may invest more than 5% of the fund's assets in any one issuer. The fund participates in the initial public offering (IPO) market. It is non-diversified.
Fund filings (PDF) »
Fund filings (PDF) »
Asset managers:
David Chan (Started: Jun 30, 1999)
Michael Del Balso (Started: Oct 25, 2000)
David Chan (Started: Jun 30, 1999)
Michael Del Balso (Started: Oct 25, 2000)
Risk
| 1 year | 3 years | 5 years | 10 years | ||
| Alpha* | 17.95 | 13.11 | 13.85 | 9.73 | |
| Beta* | 0.71 | 0.85 | 0.77 | 0.76 | |
| Mean annual return | 2.46 | 1.84 | 1.41 | 1.43 | |
| R-squared* | 37.35 | 64.83 | 60.44 | 51.18 | |
| Standard deviation | 14.32 | 17.54 | 20.40 | 16.89 | |
| Sharpe ratio | 2.05 | 1.25 | 0.82 | 0.91 | |
| * Against standard index | |||||
Top 10 holdings
| Security | Net Assets | |
| Biomarin Pharmaceutical, Inc. (BMRN) | 7.04% | |
| Alexion Pharmaceuticals, Inc. (ALXN) | 4.99% | |
| Vertex Pharmaceuticals (VRTX) | 4.79% | |
| Gilead Sciences Inc (GILD) | 4.33% | |
| Bristol-Myers Squibb Company (BMY) | 4.15% | |
| UnitedHealth Group Inc (UNH) | 3.72% | |
| Pfizer Inc (PFE) | 3.71% | |
| Biogen Idec Inc (BIIB) | 3.02% | |
| HCA Holdings Inc (HCA) | 2.99% | |
| Onyx Pharmaceuticals, Inc. (ONXX) | 2.90% |